SNCA Oligomer Binding to LAMP2A Cytosolic Tail Prevents TorsinA-Mediated LAMP2A Turnover, Stabilizing Toxic Conformations
🧪 Overview
LAMP2A protein levels are regulated post-translationally by the AAA+ ATPase torsinA, which mediates extraction of aged or damaged LAMP2A from the lysosomal membrane for degradation. This torsinA-dependent turnover normally maintains a young pool of LAMP2A with high translocation competence. In PD, SNCA oligomers bind directly to the LAMP2A cytosolic domain (residues 1-24), physically blocking the torsinA recognition motif without affecting LAMP2A's ability to form SNCA complexes. This creates a paradox: LAMP2A is functionally 'frozen' in a state capable of binding SNCA but incapable of translocating it, and simultaneously cannot be turned over. The stabilized LAMP2A-SNCA complex undergoes conformational changes that expose N-terminal epitopes, generating neoantigens recognized by autoantibodies in PD patient serum. Meanwhile, newly synthesized LAMP2A cannot accumulate because the surface pool is fully occupied. The prediction is that torsinA agonists (e.g., small molecules that enhance torsinA ATPase activity) will restore LAMP2A turnover, freeing receptors for SNCA degradation while eliminating the toxic stabilized complex.
...🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["LAMP2A Turnover<br/>TorsinA Extraction Route"]
B["Young LAMP2A Pool<br/>High CMA Translocation Competence"]
C["SNCA Oligomer Binding<br/>Cytosolic Tail Occupancy"]
D["TorsinA Recognition Blocked<br/>Damaged Receptors Retained"]
E["Toxic LAMP2A SNCA Complexes<br/>CMA Channel Dysfunction"]
F["SNCA Clearance Failure<br/>Oligomer Stabilization"]
G["Dopaminergic Neuron Stress<br/>PD Progression"]
A --> B
C -.->|"blocks"| A
C --> D
D --> E
E --> F
F --> G
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
No linked papers recorded for this hypothesis yet.
📙 Related Wiki Pages (1)
🏥 Translation
🧬 3D Protein Structure — LAMP2
No curated PDB or AlphaFold mapping for LAMP2 yet. Search RCSB →
💉 Clinical Trials (1)
Active
Completed
Total Enrolled
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LAMP2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patient-derived neurons carrying GBA1 mutations (N370S or L444P) are treated with a small-molecule torsinA ATPase agonist (e.g., Compound 43 or analog) for 24-48 hours, THEN LAMP2A protein levels w | Decreased steady-state LAMP2A protein (≥30%) and reduced LAMP2A-SNCA complex by co-IP (≥40%) in torsinA agonist-treated GBA1-PD neurons relative to vehicle cont | — no observation — | pending | 0.65 |
| IF synthetic α-synuclein oligomers (100 nM, pre-formed 24h) are applied to healthy human iPSC-derived neurons for 6-24 hours, THEN LAMP2A protein will accumulate ≥1.5-fold above baseline (indicating b | Increased LAMP2A protein (≥1.5-fold) and LAMP2A-SNCA co-IP (≥2-fold) without LAMP2A mRNA change in SNCA oligomer-treated neurons within 24 hours. | — no observation — | pending | 0.72 |
▸Metadata
| source_id | hyp-lyso-snca-548064db6357 |
| source_table | hypotheses |
| _schema_version | 1 |